Keyphrases
Actionable Genomic Alteration
100%
After Death
7%
After Surgery
7%
American Joint Committee on Cancer
7%
Anaplastic Lymphoma Kinase
15%
Biopsy-proven
7%
BRAF mutation
7%
Chemotherapy
7%
Current Smokers
7%
Epidermal Growth Factor Receptor
7%
ErbB2
7%
Failure Rate
7%
Failure Risk
7%
High Risk
7%
Human Epidermal Growth Factor Receptor 2 (HER2)
7%
Immune Checkpoint Inhibitor Therapy
15%
Immune Checkpoint Inhibitors
38%
Improved Survival
7%
Ipilimumab
7%
Lung Cancer Recurrence
7%
Major Pathological Response
7%
Median Time
15%
Molecular Diagnostics
7%
Molecular Profile
7%
Neoadjuvant
53%
Neoadjuvant Chemotherapy
7%
Neoadjuvant Immunotherapy
100%
Nivolumab
15%
Non-small Cell Lung Cancer (NSCLC)
7%
Primary Lung Cancer
23%
Resectable Lung Cancer
100%
RET Fusion
7%
Seventh Edition
7%
Squamous Cell Carcinoma (SqCC)
7%
Stage I-IIIA
7%
Survival Outcomes
7%
Time to Treatment Failure
15%
Treatment Complications
7%
Treatment Failure
38%
Tumor
38%
Tumor Molecular Profiling
7%
Viable Tumor
7%
Medicine and Dentistry
Anaplastic Lymphoma Kinase
28%
Biopsy Technique
14%
Cancer Recurrence
14%
Epidermal Growth Factor Receptor
14%
Epidermal Growth Factor Receptor 2
14%
Immune Checkpoint Inhibitor
100%
Immunotherapy
100%
Ipilimumab
14%
Lung Cancer
42%
Malignant Neoplasm
14%
Molecular Profiling
14%
Neoadjuvant Chemotherapy
14%
Neoplasm
100%
Nivolumab
28%
Non Small Cell Lung Cancer
100%
Smoking
14%
Squamous Cell Carcinoma
14%
Time to Treatment
28%
Pharmacology, Toxicology and Pharmaceutical Science
Anaplastic Lymphoma Kinase
28%
Cancer Recurrence
14%
Chemotherapy
28%
Epidermal Growth Factor Receptor
14%
Epidermal Growth Factor Receptor 2
14%
Immune Checkpoint Inhibitor
100%
Immunotherapy
100%
Ipilimumab
14%
Lung Cancer
42%
Malignant Neoplasm
14%
Neoplasm
100%
Nivolumab
28%
Non Small Cell Lung Cancer
100%
Squamous Cell Carcinoma
14%